AUA 2017 - Results from #180

Viewing 181-200 of 344 articles

AUA 2017:Non-Muscle Invasive Bladder Cancer Guidelines

AUA 2017: High Risk Non-Muscle Invasive Bladder Cancer

AUA 2017: What is Best Systemic Therapy for Metastatic/Invasive Bladder Cancer?

AUA 2017: What is the Best Imaging and What Will We Be Using in the Future: Cystoscopy and Cross-Sectional Imaging?

AUA 2017: Beyond Cytology: What is the Urinary Marker We Should Use Now and What Will Be the Best in the Future?

AUA 2017: Best Urothelial Cancer papers from 2016

AUA 2017: How I Screen - Panel

AUA 2017: Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): final results and translational findings of an open-label, single-arm, phase 2 study

AUA 2017: Development and external validation of a novel 12-gene signature on muscle-invasive bladder cancer for prediction of overall survival: linkage to data from The Cancer Genome Atlas

AUA 2017: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy

AUA 2017: Genome Drivers of Response to Existing and Emerging Therapies in Bladder Cancer

AUA 2017: Creating an Institution-Wide Systems Biology Initiative

AUA 2017: Studying Niche Populations: Neuroendocrine Prostate Cancers

AUA 2017: Leveraging the Power of Ultra-Deep Sequencing (When Deep Sequencing Fails)

AUA 2017: Opportunities and Challenges Associated with Big Data

AUA 2017: Prospective Study Of Biopsy Decipher Scores In Potential Candidates For Active Surveillance

AUA 2017: Multiparametric-MRI Prior To Repeat Biopsy For Active Surveillance Can Identify Men With High-risk Prostate Cancer

AUA 2017: Concordance Between Physician-documented Versus Patient-reported Comorbidities In Prostate Cancer: Validation Of A Novel Informatics Tool

AUA 2017: Worldwide Variation In Determinants For Inclusion And Follow-up In Active Surveillance For Low-risk Prostate Cancer: Results Of The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative

AUA 2017: Association Between Germline Genetic Variation And Progression In Men With Low-risk Prostate Cancer On Active Surveillance

5
6
7
8
9
10
11
12
13
14